Skip to main content
PLOS One logoLink to PLOS One
. 2022 Jul 18;17(7):e0271568. doi: 10.1371/journal.pone.0271568

The microeconomic impact of out-of-pocket medical expenditure on the households of cardiovascular disease patients in general and specialized heart hospitals in Ibadan, Nigeria

Folashayo Ikenna Peter Adeniji 1,*, Akanni Olayinka Lawanson 2, Kayode Omoniyi Osungbade 1
Editor: Hao Xue3
PMCID: PMC9292125  PMID: 35849602

Abstract

Background

Cardiovascular diseases (CVDs) present a huge threat to population health and in addition impose severe economic burden on individuals and their households. Despite this, there is no research evidence on the microeconomic impact of CVDs in Nigeria. Therefore, this study estimated the incidence and intensity of catastrophic health expenditures (CHE), poverty headcount due to out-of-pocket (OOP) medical spending and the associated factors among the households of a cohort of CVDs patients who accessed healthcare services in public and specialized heart hospitals in Ibadan, Nigeria.

Methods

This study adopts a descriptive cross-sectional study design. A standardized data collection questionnaire developed by the Initiative for Cardiovascular Health Research in Developing Countries was adapted to electronically collect data from all the 744 CVDs patients who accessed healthcare services in public and specialized heart hospitals in Ibadan between 4th November 2019 to the 31st January 2020. A sensitivity analysis, using rank-dependent thresholds of CHE which ranged from 5%-40% of household total expenditures was carried out. The international poverty line of $1.90/day recommended by the World Bank was utilized to ascertain poverty headcounts pre-and post OOP payments for healthcare services. Categorical variables like household socio-demographic and clinical characteristics, CHE and poverty headcounts, were presented using percentages and proportions. Unadjusted and adjusted logistic regression models were used to assess the factors associated with CHE and poverty. Data were analyzed using STATA version 15 and estimates were validated at 5% level of significance.

Results

Catastrophic OOP payment ranged between 3.9%-54.6% and catastrophic overshoot ranged from 1.8% to 12.6%. Health expenditures doubled poverty headcount among households, from 8.13% to 16.4%. Having tertiary education (AOR: 0.49, CI: 0.26–0.93, p = 0.03) and household size (AOR: 0.40, CI: 0.24–0.67, p = 0.001) were significantly associated with CHE. Being female (AOR: 0.41, CI: 0.18–0.92, p = 0.03), household economic status (AOR: 0.003, CI: 0.0003–0.25, p = <0.001) and having 3–4 household members (AOR: 0.30, CI: 0.15–0.61, p = 0.001) were significantly associated with household poverty status post payment for medical services.

Conclusion

OOP medical spending due to CVDs imposed enormous strain on household resources and increased the poverty rates among households. Policies and interventions that supports universal health coverage are highly recommended.

Background

Cardiovascular diseases (CVDs) represent a major cause of morbidity and mortality [1, 2]. Globally, CVDs accounted for roughly 330 million Disability Adjusted Life Years (DALYs) lost in 2013 [3]. Likewise, a report published by the World Health Organization (WHO) revealed that these health conditions are responsible for approximately 17.9 million deaths worldwide every year, which translates to about one-third of global mortality [4, 5]. In addition to the impacts of CVDs on public and population health, heart-related diseases impose substantial economic burdens on individuals and the society [69]. In 2010 alone, the global cost of CVDs was staggering, estimated at approximately US$863 billion and this is predicted to rise to almost US$1044 billion by 2030, representing about a 7.3 percent increase during that time [10].

At patient and household levels, CVDs, like every chronic illness, have the potential to cause severe financial hardship due to the increase in the demand for medical services and a consequent rise in household health expenditures, especially in low-and-middle-income countries (LMICs) where the burden of out-of-pocket (OOP) payment remains high [11]. A study conducted to investigate the financial consequence of OOP for medical services revealed that an increasing number of households are incurring catastrophic health expenditures (CHE) and are being pushed into poverty in LMICs [12]. In episodes of health shocks many households de-save and/or resort to borrowing and selling of assets to offset medical bills. In some cases, individuals may not seek healthcare services either due to the inability to pay or as a result of the fear of being impoverished due to medical spending. These oftentimes undermine the goal of equity and equality of access to health care. Similarly, when the costs of treating chronic diseases such as CVDs is disproportionately borne by individuals and households, it results in serious financial catastrophe [13]. This scenario is even worse for households already within the margin of poverty. Although the outcome of impoverishment resulting from CHE can ordinarily be experienced by households, however, it is often aggravated when a member of the household suffers any form of chronic disease. In general, households with lower health stock as a result of ill-health coupled with limited financial protection are often predisposed to impoverishment.

In Nigeria, the health insurance infrastructure remains underdeveloped. Presently, only a small proportion, about 5%, of the population is covered by the financial protection provided under the National Health Insurance Scheme (NHIS) [14]. Meanwhile, individuals covered under this scheme are majorly federal government workers. Other individuals are either able to pay insurance premium to be enrolled in any form of private insurance or remain uninsured. In particular, the economically less viable individuals who are oftentimes found in the informal sector are disproportionately disadvantaged with regards to access to healthcare insurance in the country. Consequently, individuals and households in this group, especially those with chronic health conditions like CVD face increasing risk of incurring CHE which is capable of widening the gap between the rich and the poor and causing a vicious cycle of poverty.

Recently, a number of studies have reported that the burden of CVDs are rising in Nigeria, like in many other sub-Saharan Africa (SSA) countries [15, 16]. But, there has been no disease-specific studies examining the household-level microeconomic impact of OOP payments for the treatment of CVDs in Nigeria. This studies fills this gap by estimating the CHE headcount, the impoverishing effects of medical expenditures as well as the factors associated with CHE and the poverty induced by healthcare spending among patients who accessed healthcare services in general and specialized heart hospitals in Ibadan, Nigeria. Findings in this study will be beneficial for re-iterating the need for achieving equity in healthcare financing in Nigeria, and indeed, in other SSA countries.

Conceptual framework

The analysis in this paper follows the framework depicted in Fig 1 in a manner that assesses the economic consequence related to OOP expenditures (i.e. both direct and indirect costs) of treating cardiovascular diseases among patients. Without access to a well-developed prepayment system for the consumption of health care, the overall economic burden of accessing healthcare may have cascading/spill-over effects on the economic welfare of individuals and their households. There are usually heterogeneous microeconomic impacts of OOP medical expenditures which is often dependent on the differentials in the income status of individual/households. Economically less viable patients and their families incur CHE and may even be impoverished due to OOP health expenditures. In the literature, there is evidence that for countries without optimal health insurance infrastructure, uninsured patients are faced with the risk of experiencing 2–7 fold higher levels of CHE relative to insured patients [17].

Fig 1. The microeconomic impact of cardiovascular disease on individuals and households.

Fig 1

Adapted from McIntyre et al. 2006, pp. 860.

Methods

Study design and population

This study adopted a descriptive cross-sectional study design. Participants were patients who were clinically diagnosed to have any of the CVDs and who accessed outpatient and inpatient healthcare services at tertiary and secondary public hospitals, and private specialized cardiac clinics (a total of 5 hospital facilities) within the Ibadan metropolis. Ibadan is a large city in Southwest, Nigeria and the city is renowned as the biggest city in West Africa with respect to land mass. The tertiary hospital included in this study serves as a major referral center for patients seeking healthcare services due to chronic illnesses in Nigeria.

Sample size, sample selection and study duration

According to Johnston et. al. [18], to estimate the sample size for a continuous outcome variable like OOP health payments and assuming that mean (average) cost μ and standard deviation σ are normally distributed. The width of the precision of a given sample size according can be expressed as:

(W=1.96×σn)2 (1)

However, studies with appropriate value for σ are rare, therefore to resolve this, Johnston et. al. recommended the following formula:

(1.96×CvV)2 (2)

where Cv denote the coefficient of variation (i.e. the ratio of the standard deviation and the mean cost), V represent the desired level of precision which is 95% confidence interval (CI). The Cv for a 95% CI is 0.50. Thus, the minimum sample size was determined as follows:

n=(1.96×0.500.05)2=384 (3)

Adjusting the sample size for 10% non-response rate:

nf=n1NR (4)

Where nf denotes non-response and NR, non-response rate

nf=38410.1=427 (5)

In Ibadan, there is one Federal government owned tertiary hospital facility, two State government owned secondary hospitals with capacities to attend to patients with acute and chronic diseases and three specialized heart hospitals. Data was collected from these hospital facilities and a total sampling of all the 744 CVDs patients who accessed healthcare services from those hospitals between 4th November 2019 to the 31st January 2020 was carried out. Three hundred and thirty-eight patients were recruited from the tertiary hospital, 368 from the two public secondary health facilities and 38 from all the three specialised heart hospitals

Data collection and quality control

A standardized data collection questionnaire developed by the Initiative for Cardiovascular Health Research in Developing Countries and used in a previous study [19] was adapted for this study. The instrument elicited information on patients’ socio-demographic characteristics, medical/clinical profile, OOP payments for outpatient and inpatient care (for those who had been hospitalized). Also, the respondents were asked to provide the monthly average food and non-food expenditure incurred by their various households. The OOP expenditures includes payment for hospital fees, medicines/drugs, laboratory tests, hospital bed, costs of surgery, emergency room, transportation to and from the hospital and the costs of food during hospital admission. To contextualize and validate the data collection tool, a pre-test was carried out. Data was collected from 43 respondents which represents 10% of the minimum sample size. Two hospital facilities apart from the ones included in the study were used for this purpose. The data collected during the pre-test was not included in the final analysis.

Trained research assistants collected data electronically using the Redcap software [20]. Patients who were attending outpatient clinic were interviewed. Also, patients who had been hospitalized 1 year prior to the period of data collection were asked to provide the health expenditures incurred during their hospital stay. Having co-morbidities could potentially bias cost estimates, therefore, participants were asked to report only the OOP expenditures (both direct and indirect costs) pertaining to CVD treatment.

Quality control was ensured through strict supervision of the data collection process. In some cases, random verification was conducted by reviewing hospital records and through random phone calls to patients and/or their caregivers. The validation of data was carried out on a daily basis by two trained research supervisors. The total expenditures per outpatient visits and the number of monthly outpatient visits were collected. With this, the annual outpatient OOP health expenditure was calculated. This same procedure was followed to annualize OOP payments for inpatient care. These were summed up for patients who assessed both outpatient and inpatient care. All expenditures were collected in the Nigerian Naira (NGN).

Variables

In this study, the primary outcome variables are CHE headcount and the impoverishing effect of healthcare spending that is related to CVDs treatment. Also, the explanatory variables are respondents’ age, gender, educational level, marital status, occupation, existence of comorbidity, whether the respondent was hospitalized in the last 12 months or not, household size as well as household income.

The microeconomic impact of OOP expenditure

The measure of the microeconomic impact of OOP spending for healthcare service in this study is rather a narrow one as it only considered the CHE headcount and the impoverishment induced by medical expenditures among a cohort of CVDs patients. Specifically, the analysis of the incidence of CHE and the impoverishing effects of healthcare expenditures were carried out at household level following the procedure adopted in previous studies [2127].

The measure of CHE

The concept of CHE has been described as the OOP healthcare expenditure over a predetermined proportion, (z%), of household income/resources which is capable of predisposing them to financial distress [28, 29]. However, there is no consensus regarding a specific threshold over which medical spending can be adjudged to be catastrophic given that households have varying income levels and applying a blanket threshold may be less plausible. Instead, studies have used different thresholds ranging from 5% to 40% of household total income (or total non-food expenditure in the case of 40% threshold), a form of sensitivity analysis, to ascertain the incidence of CHE [30]. This study favored the “rank-dependent threshold” approach for determining CHE proposed by Ataguba [21, 31]. This methodology adjusts for vertical equity as well as the diminishing marginal rate of income when examining the catastrophic impact of OOP medical expenditures on household resources [21]. The intuition behind Ataguba’s approach is that for low income households, spending a relatively small proportion of their resources to purchase healthcare services may be catastrophic while richer households will need to spend a much higher proportion of their income to experience financial catastrophe. Following Ataguba’s work, a rank-dependent threshold, z!(%), is a function of a parameter of aversion to inequality, γ, households’ income percentile, p, and the initial threshold, z%. This is expressed as follows:

z!(%)=f(p:γ)*z%,f(p:γ)=γ(1p)(γ1),γ(0,1) (6)

In this study, γ = 0.8 and z% = 5%, 10%, 20%, 25% of total household expenditure and 40% of total household non-food expenditure or capacity to pay, respectively. Parameter γ is less than 1 if households in the lower income strata face lower CHE thresholds (which is our objective in this paper) relative to richer households and vice versa. Aversion to inequality was first popularized by Donaldson and Weymark [32], and has been used by Ataguba to implement the rank-dependent threshold, setting it to equal to 0.8 [21, 33]. In computing the CHE incidence, household expenditure was used as a proxy for household income because the former tends to be more accurately reported and is often slightly impacted by short-run fluctuations relative to household income. Also, individuals tend to be disposed to revealing their expenditures compared to their willingness to disclosing their income, especially in developing countries. As such, household consumption expenditures better reflects the living standard of households [24, 34]. Hence, to ascertain the CHE headcount, the rank-dependent catastrophic overshoot, Oi!, which captures the intensity of catastrophic OOP medical spending among households, was defined as:

Oh!=max(0,(OOPhTEhorTnfEh))z!(%) (7)

where OOPh denotes OOP medical expenditure, TEh, total household expenditure and TnfEh, total household non-food expenditure (also referred to as capacity to pay). Applying the z!(%) to household income and denoting whether a household incurred CHE or not by Eh! (i.e. Eh!=1 if household incurred CHE and 0, if otherwise), rank-dependent CHE headcount, CH! is given as:

CH!=1N(h=1NEh!)=μE! (8)

where N denotes the sample size and μE!!, the mean of E!. Also, the mean rank-dependent positive gap (MPG), like the rank-dependent catastrophic overshoot, reflects the intensity of CHE and it is defined as:

MPG!=h=1NOh!h=1NEh!=μO!μE!forOh!>0 (9)

Measure of the impoverishing effect of OOP medical expenditure

This measures the increase in the incidence of poverty due to OOP health spending. To evaluate this, the international poverty line of $1.90/day recommendation by the World Bank was utilized [35]. Following this, the poverty incidence pre and post OOP payment for medical services among CVDs patients were estimated thus:

Hpre=1N(h=1NPhpre)=μPpre (10)
Hpost=1N(h=1NPhpost)=μPpost (11)

where Hpre and Hpost respectively depict the poverty incidence before and after the OOP medical expenditure was considered. Also, the difference in both estimates represents the impact of OOP health spending on poverty headcount [21, 33].

Analysis

Categorical variables like household socio-demographic characteristics, CHE and poverty headcount were presented using percentages and proportions. Logistic regression models were used to assess the factors associated with CHE and poverty. The variables related to the experience of CHE and household poverty status post payment for medical services due to CVDs treatment were examined. Data were analyzed using STATA version 15 and estimates were validated at 5% level of significance.

Ethics approval and consent to participate

Voluntary informed and written consent was obtained from individual respondents before the commencement of data collection. Ethical approval was obtained from the University of Ibadan/University College Hospital ethics review committee (NHREC/05/01/2008a). Approval was also obtained from respective hospital facilities.

Results

The socio-demographic characteristics of CVDs patients are presented in Table 1. Majority of the patients were within the age range of 45–74 years. There were more females (68.55%) relative to the number of males. Also, about 28.36% of the respondents had primary education, 27.28%, tertiary education, 24.73%, secondary education while 19.62% had no formal education. The respondents are mostly married: 515 in total accounting for 69.22% of the patients, while more than one-third (26.88%) of the respondents were those who had lost their spouse. A few 14 (1.88%) were either divorced or separated and only 15 (2.02%) were single. Relating to the occupational distribution of the respondents, 477, representing 64.11% were gainfully employed. Out of which 265 (35.62%) were self-employed, 65 (8.74%) were civil servants employed by government, 19 (2.55%) were employed in private organisation settings, while 128 (17.2%) were artisans. On the other hand, 267 (35.89%) were not gainfully employed, of which, A total of 152 respondents (20.43%) were retirees, while 100 (13.44%) were unemployed, and 15 (2.02%) were disabled/cannot work. In terms of household position, majority of the respondents were mothers (67.48%) while 214 (28.88%) were fathers. Similarly, 67.61% of the respondents were from households with 1–4 household size while 28.49% were from household size of 5–8 inhabitants. Patients who reported household size between 9–12 inhabitants were 24 (3.23%), while those from household size above 12 inhabitants were the least (0.67%).

Table 1. Socio-demographic characteristics of CVDs patients accessing healthcare in public and private hospitals in Ibadan (N = 744).

Variables Frequency Percent (%)
Age Group (Years)
<45 76 10.22
45–54 133 17.88
55–64 206 27.69
65–74 224 30.11
>74 105 14.11
Gender
Male 234 31.45
Female 510 68.55
Educational Level
None 146 19.62
Primary 211 28.36
Secondary 184 24.73
Tertiary 203 27.28
Marital Status
Single 15 2.02
Divorced/Separated 14 1.88
Widow/Widower 200 26.88
Married 515 69.22
Occupation
Employed (government) 65 8.74
Employed (non-government) 19 2.55
Employed (self) 265 35.62
Unemployed 100 13.44
Retired 152 20.43
Artisan 128 17.2
Disabled/Cannot work 15 2.02
Household Position
Father 214 28.88
Mother 500 67.48
Son 16 2.16
Daughter 9 1.21
Others 2 0.27
Patients’ Household size
1–4 503 67.61
5–8 212 28.49
9–12 24 3.23
>12 5 0.67

Note: Others refers to individuals residing in the household but are not part of the nuclear family

The clinical profile of respondents is shown in Table 2. Majority (84.01%) of the patients were diagnosed with hypertensive heart disease while 33 (4.44%) and 29 (3.9%) had dilated cardiomyopathy and ischaemic heart disease, respectively. The CVD with the lowest frequency (0.13%) was cor pulmonale. Of the respondents, 299 (40.19%) reported having other co-morbid conditions. Of the CVDs patients, 60.89% reported visiting the hospital once every month and only 2.15% visited the hospital more than four times on average. One hundred and twenty-eight (17.41%) reported hospitalization in the last one year, with majority of them (81.25%) reporting that they were hospitalized once during that time.

Table 2. Clinical characteristics of CVDs patients accessing healthcare in public and private hospitals in Ibadan (N = 744).

Health Issue Frequency Percent (%)
Heart-related-Condition
Alcoholic cardiomyopathy 3 0.4
Anaemic heart failure 16 2.15
Complete heart block 6 0.81
Congenital heart disease 5 0.67
Cor pulmonale 1 0.13
Dilated cardiomyopathy 33 4.44
Hypertensive heart disease 625 84.01
Ischaemic heart disease 29 3.9
Pericardial valvular heart disease 7 0.94
Peripartum cardiomyopathy 5 0.67
Thyroid disease 3 0.4
Other 11 1.48
Comorbidity
No 445 59.81
Yes 299 40.19
Frequency of visit to health Facility in a month
Once 453 60.89
Twice 147 19.76
Thrice 89 11.96
Four times 38 5.24
> 4 times 17 2.15
Hospitalized in the last 12months?
No 607 82.59
Yes 128 17.41
No of time hospitalized
Once 104 81.25
Twice 18 14.06
Thrice 4 3.13
Five times 2 1.56

Table 3 shows the incidence and magnitude of CHE incurred by the households of CVDs patients. At 5% initial threshold, the CHE headcount was 54%. The level of financial catastrophe decreased as the thresholds increased. For the 40 percent threshold where the non-food expenditure was used as the denominator, 7.8% of the households incurred CHE. The catastrophic overshoot ranged from 1.8% at 25% initial threshold to 12.6% at 5% threshold. Similarly, the mean positive gap ranged between 23.1% and 47%.

Table 3. Incidence and intensity of catastrophic out-of-pocket medical expenditures among CVDs patients accessing healthcare in public and private hospitals in Ibadan.

Initial threshold (z%) 5% 10% 15% 20% 25% 40%
Catastrophic headcount (CH!) 54.6% 33.4% 21.4% 10.0% 3.9% 7.8%
Catastrophic overshoot (Oi!) 12.6% 10.9% 6.3% 4.7% 1.8% 2.2%
Mean positive gap (MPG!) 23.1% 32.6% 29.4% 47.0% 46.2% 28.2%

Note: Estimates were generated at household level. The households of all the 744 patients were included in the analysis

The computed poverty headcount pre and post deduction of OOP medical expenditures is presented in Table 4. The level of poverty was 8.13% before accounting for the monetary outlays towards accessing treatment due to CVDs. This doubled post payment for healthcare services as a further 61 households were impoverished, and consequently, the level of poverty rose to 16.4%.

Table 4. Poverty headcount before and after accounting for out-of-pocket medical expenditures among the households CVDs patients accessing healthcare in public and private hospitals in Ibadan (N = 744).

Poverty headcount before accounting for OOP health payments Frequency Percent (%)
Poor 60 8.13
Non-poor 678 91.87
Poverty after accounting for OOP health payments
poor 121 16.4
non-poor 617 83.6

Note: Estimates were generated at household level. The households of all the 744 patients were included in the analysis. Poverty headcount was computed at the World Bank recommended $1.90 per day.

The distribution of the factors related to the risk of experiencing CHE is presented in Table 5A and 5B. In the unadjusted logistic regression, households of CVDs patients within the 65–74 years and above 74 years age groups were significantly more likely to incur CHE relative to respondents of ages less than 45 years (OR: 1.46, CI: 0.59–2.43 and OR: 2.27, CI: 0.93–4.65, respectively). Similarly, at 10% threshold, respondents within age groups 55–64 years, 65–74 years and ages above 74 years were twice, thrice and four times more likely to incur CHE (OR: 2.03, CI: 1.04–3.97; OR: 3.55, CI: 1.84–6.83; OR: 4.24, CI: 2.09–8.62) compared with respondents within ages less than 45 years. Also, the level of education of patients is significantly associated with the risk of incurring CHE. Participants who had tertiary education were less likely to experience CHE compared with those who had no formal education at 5% threshold (AOR: 0.49, CI: 0.26–0.93, p = 0.03). Similarly, at 10% threshold, CVDs patients who had secondary and tertiary education were significantly less likely to experience CHE (OR:0.62, CI:0.39–0.99; OR:0.51, CI:0.32–0.81) relative to those who had not been formally educated. This pattern was also observed for the economic status of households. At both 5% (OR:0.22, CI:0.14–0.36, p = <0.01) and 10% (OR: 0.24, CI: 0.13–0.41, p = 0.01) thresholds, the richest households (households in quintile 5) were less likely to experience CHE compared with patients from the poorest households (quintile 1). Retired and unemployed CVDs patients were significantly more likely to incur CHE (OR:1.91; CI: 1.06–3.45, p = 0.03 and OR:1.99, CI: 1.06–3.76, p = 0.03). Patients who reported that they live in households with 5 or more household members were less likely to incur CHE relative to those from households with 1–2 members (OR:0.4, CI:0.27–0.59, p = <0.01). This was also significant in the unadjusted and adjusted models at 10% threshold (OR: 0.26, CI: 0.17–0.40, p = 0.001, AOR: 0.40, CI: 0.24–0.67, p = 0.001).

Table 5. Unadjusted and adjusted logistic regression of the factors associated with catastrophic health expenditure among the households of CVDs patients accessing healthcare in public and private hospitals in Ibadan (N = 744).

5% 10%
Unadjusted Adjusted Unadjusted Adjusted
OR 95%CI p-Value AOR 95%CI p-Value OR 95%CI p-Value AOR 95%CI p-Value
a)
Age Group (Years)
<45 (Ref)
45–54 1.05 0.59, 1.84 0.88 0.94 0.48, 1.83 0.85 1.47 0.72, 3.03 0.29 1.17 0.54, 2.54 0.69
55–64 1.46 0.86, 2.48 0.16 1.07 0.55, 2.09 0.84 2.03 1.04, 3.97 0.04 1.06 0.49, 2.25 0.89
65–74 1.78 1.05, 3.02 0.03 1.20 0.59, 2.43 0.61 3.55 1.84, 6.83 0.001 1.46 0.67, 3.17 0.34
>74 2.27 1.24, 4.15 0.01 2.08 0.93, 4.65 0.74 4.24 2.09, 8.62 0.001 2.11 0.90, 4.92 0.09
Gender
Male (Ref)
Female 0.94 0.69, 1.28 0.71 0.81 0.58, 1.12 0.20
Educational Level
None (Ref)
Primary 1.25 0.81, 1.93 0.32 1.01 0.62, 1.65 0.97 1.06 0.69, 1.63 0.80 0.97 0.59, 1.57 0.899
Secondary 0.66 0.42, 1.02 0.06 0.58 0.34, 0.99 0.05 0.62 0.39, 0.99 0.04 0.71 0.41, 1.22 0.215
Tertiary 0.62 0.40, 0.95 0.03 0.49 0.26, 0.93 0.03 0.51 0.32, 0.81 0.004 0.59 0.31, 1.13 0.113
Income      
Quintile 1 (Ref)      
Quintile 2 1.17 0.72, 1.92 0.53 1.19 0.71, 2.01 0.51 1.37 0.86, 2.18 0.18 1.49 0.90, 2.46 0.124
Quintile 3 0.63 0.39, 1.01 0.06 0.66 0.39, 1.12 0.12 0.71 0.44, 1.14 0.15 1.04 0.62, 1.76 0.882
Quintile 4 0.66 0.41, 1.07 0.09 0.77 0.44, 1.35 0.36 0.41 0.25, 0.68 0.001 0.65 0.36, 1.17 0.151
Quintile 5 0.22 0.14, 0.36 <0.001 0.27 0.15, 0.49 0.001 0.24 0.13, 0.41 0.001 0.43 0.22, 0.83 0.012
Marital Status
Single (Ref)
Divorced/Separated 5.50 1.06, 28.42 0.04 4.06 0.54, 30.29 0.17 4.88 0.78,30.29 0.09
Widow/Widower 1.63 0.56, 4.75 0.37 0.41 0.11, 1.59 0.20 3.94 0.87, 17.96 0.08
Married 1.87 0.66, 5.33 0.24 0.94 0.26, 3.45 0.09 3.06 0.68, 13.73 0.14
Household Size      
1–2 (Ref)      
3–4 0.75 0.52, 1.09 0.13 0.95 0.63, 1.44 0.80 0.50 0.35, 0.72 0.001 0.59 0.39, 0.88 0.011
5 and above 0.4 0.27, 0.59 0.001 0.66 0.41, 1.07 0.09 0.26 0.17, 0.40 0.001 0.40 0.24, 0.67 0.001
b)
Occupation
Employed (government) (Ref)
Employed (non-government) 0.79 0.27, 2.29 0.67 0.64 0.20, 2.04 0.45 0.55 0.11, 2.73 0.47 0.47 0.09, 2.46 0.37
Employed (self) 1.56 0.90, 2.69 0.11 0.90 0.45, 1.80 0.77 2.83 1.44, 5.54 0.003 1.50 0.67, 3.34 0.32
Unemployed 1.99 1.06, 3.76 0.03 1.13 0.49, 2.59 0.78 3.12 1.48, 6.57 0.003 1.37 0.56, 3.36 0.50
Retired 1.91 1.06, 3.45 0.03 1.10 0.53, 2.26 0.80 3.03 1.49, 6.13 0.002 1.50 0.66, 3.43 0.33
Artisan 1.18 0.65, 2.16 0.58 0.58 0.27, 1.24 0.16 1.03 0.48, 2.22 0.94 0.43 0.17, 1.07 0.07
Disabled/Cannot work 0.93 0.29, 2.99 0.90 0.40 0.10, 1.48 0.17 1.20 0.29, 4.99 0.80 0.34 0.07, 1.58 0.17
Comorbidity
No (Ref)
Yes 0.99 0.74, 1.34 0.96 1.01 0.74, 1.39 0.93
Hospitalized
No (Ref)
Yes 1.34 0.91, 2.0 0.14 0.86 0.57, 1.29 0.46

Note: Income quintile relates to households’ income (quintile 1 for the poorest households and quintile 5 for the richest). Other variables are strictly patients’ characteristics.

The distribution of factors associated with poverty after accounting for out-of-pocket medical expenditures is presented in Table 6A and 6B. Respondents in age groups 55–64 years, 65–74 years and ages above 74 years were significantly more likely to be poor (OR: 3.49, CI:1.19-10-22, p = 0.02; OR: 5.13, CI: 1.78–14.74, p = 0.002; OR: 5.33, CI: 1.77–16.10, p = 0.003) and were exposed to a higher risk of impoverishment due to OOP medical payments relative to those below the age of 45 years. Female patients were less likely to be poor compared to males (AOR: 0.41, CI: 0.18–0.92, p = 0.03). Respondents who had secondary education (OR: 0.33, CI: 0.18–0.60, p = <0.001) and those who had tertiary education (OR: 0.22, CI: 0.11–0.41, p = < 0.001) were less likely to be poor relative to CVD patients with no formal education. The economic status of the households of patients is significantly associated with their poverty status. The richest households were less likely to be poor relative to those in the lowest income category (AOR: 0.003, CI: 0.0003–0.25, p = <0.001). Also, households with 3–4 members were less likely to be poor compared with those with 1–2 members (AOR: 0.30, CI: 0.15–0.61, p = 0.001).

Table 6. Unadjusted and adjusted logistic regression of the factors associated with poverty after accounting for out-of-pocket medical expenditures among CVDs patients accessing healthcare in public and private hospitals in Ibadan (N = 744).

  Unadjusted Adjusted
OR 95%CI P-Value AOR 95%CI P-Value
a)
Age Group (Years)            
<45 (Ref)            
45–54 1.62 0.50, 5.29 0.42 1.05 0.18, 6.21 0.96
55–64 3.49 1.19, 10.22 0.02 1.96 0.39, 9.96 0.42
65–74 5.13 1.78, 14.74 0.002 1.17 0.22, 6.16 0.85
>74 5.33 1.77, 16.10 0.003 0.98 0.16, 5.92 0.98
Gender            
Male (Ref)            
Female 1.65 1.05, 2.60 0.03 0.41 0.18, 0.92 0.03
Educational Level            
None (Ref)            
Primary 0.77 0.47, 1.26 0.3 0.84 0.37, 1.89 0.68
Secondary 0.33 0.18, 0.60 <0.001 0.49 0.18, 1.33 0.16
Tertiary 0.22 0.11, 0.41 <0.001 0.20 0.05, o.74 0.016
Income
Quintile 1 (Ref)
Quintile 2 0.050 0.026, 0.096 <0.001 0.028 0.013, 0.06 <0.001
Quintile 3 0.006 0.001, 0.027 <0.001 0.004 0.001, 0.20 <0.001
Quintile 4 0.007 0.0016, 0.03 <0.001 0.007 0.001, 0.03 <0.001
Quintile 5 0.003 0.0004, 0.024 <0.001 0.003 0.0003, 0.25 <0.001
Marital Status            
Single (Ref)            
Divorced/Separated 0.31 0.03, 3.38 0.34      
Widow/Widower 1.52 0.41, 5.60 0.53      
Married 0.56 0.15, 2.04 0.38      
Household Size
1–2 (Ref)
3–4 4.02 2.19, 7.37 <0.001 0.30 0.15, 0.61 0.001
5 and above 9.25 3.81, 22.44 <0.001 0.41 0.15, 1.14 0.088
b)
Occupation            
Employed (government) (Ref)            
Employed (non-government) 1.91 0.32, 11.35 0.48 0.60 0.03, 6.21 0.55
Employed (self) 3.13 1.08, 9.06 0.04 0.76 0.13, 5.01 0.83
Unemployed 7.62 2.55, 22.78 <0.001 2.01 0.30, 13.98 0.46
Retired 2.35 0.77, 7.16 0.13 0.64 0.12, 4.11 0.71
Artisan 2.04 0.65, 6.43 0.22 0.20 0.03, 1.38 0.10
Disabled/Cannot work 2.35 0.39,14.19 0.35 0.76 0.028, 9.36 0.65
Comorbidity            
No (Ref)            
Yes 0.76 0.51, 1.14 0.19      
Hospitalized            
No (Ref)            
Yes 0.76 0.44, 1.32 0.33      

Note: Income quintile relates to households’ income (quintile 1 for the poorest households and quintile 5 for the richest). Other variables are strictly patients’ characteristics.

Discussion

This study assessed the microeconomic impact of OOP medical expenditures by estimating the incidence and extent of CHE, the poverty headcount pre and post-payment of OOP medical expenditures as well as the associated factors among CVDs patients accessing healthcare services at public and private hospital facilities in Ibadan, Nigeria. Findings revealed that having to pay OOP for medical services predisposes CVDs patients to incurring CHE and also increased the poverty rate among the households of those patients. The incidence of financial catastrophe is expectedly the highest when a 5% threshold is used, as a staggering 54.6% of the households of CVDs patients incurred CHE. Although, the CHE headcount decreased with higher thresholds, the level of financial strain on household resources was enormous with respect to the level of CHE for the other thresholds explored.

Furthermore, the study revealed a high intensity and magnitude of CHE among the study population, with this ranging between 2.2%-12.6% for the catastrophic overshoot and between 23.1%-47.0% for the mean positive gap. Given the enormous costs of treating most chronic diseases like CVDs, the evidence in this study is supported by findings in previous studies conducted in LMICs where there remains a substantial burden of OOP payments due to underdeveloped of health insurance mechanisms. Tolla et al. [36] carried out a study that investigated the CHE induced by OOP health expenditures related to CVD prevention and treatment in Addis Ababa, Ethiopia. The authors found that 27 percent of those who accessed CVD care experienced CHE with the poorest households having 60-fold chance of incurring CHE relative to households with the highest economic status. Another study investigated the incidence of financial catastrophe among patients who received inpatient care due to acute coronary event in selected countries in Asia [37]. The study revealed that the burden of CHE was substantial as 66% level of CHE was reported among patients who incurred OOP medical expenditures and are without any form of financial protection in terms of health insurance. This level of CHE appears to be significantly higher compared to the one obtained in this present study. However, a study implemented in India to investigate the CHE headcount among individuals ailing with acute coronary syndrome, reported a relatively much higher incidence of CHE. The study reported that 84 percent of the patients experienced CHE as a result of healthcare spending for the treatment of an episode of acute coronary event [38]. A study that reported a similar incidence of financial catastrophe was that conducted to ascertain the microeconomic effect of OOP payments among hospitalized CVDs patients in four LMICs, Argentina, China, India and Tanzania [19]. The authors stated that more than half of the study participants experienced CHE. Presumably, the level of CHE generated in the reviewed studies would have been impacted by the varying characteristics of the health systems like the quality and cost of health care in the countries where the studies were conducted. For instance, the quality of health infrastructure and thus the quality of healthcare services is often reflected on how much it costs to access healthcare. Also, the heterogeneous methodologies employed in determining the level of CHE may partly be responsible for the different estimates of financial catastrophe. This view aligns with the conclusions made in previous studies [3941]. Overall, there is abundant research evidence globally that OOP medical expenditures for the treatment of CVDs are quite large and capable of subjecting individuals and their families to financial distress, especially in LMICs where OOP medical expenditures remains the principal source of healthcare financing.

Another evidence revealed in this study is that OOP expenditures due to CVDs treatment among patients had a huge impact on household resources and predisposed them to impoverishment. Specifically, after accounting for health spending towards accessing healthcare services, the poverty rate of patients’ households doubled, from 8.13% to 16.4%. This may not augur well for the realization of the goal of poverty reduction as articulated in the Sustainable Development Goals (SDGs). Previous studies have also reported the impoverishing effects of healthcare expenditures in developing countries. A study implemented to estimate the impoverishing effects of health expenditures due to chronic illnesses among household in India revealed that having to pay OOP doubled the poverty rate within the study population [42]. Likewise, Barasa et al. examined the poverty impact of direct and indirect OOP healthcare spending in Kenya. The study found that 619,541 Kenyans are impoverished annually due to OOP medical outlays [26]. A similar study conducted in Egypt reported that there was a 7.4% increase in poverty rate that is attributable to OOP payments for healthcare services among households [43]. Moreover, many other studies have reported similar findings [4447].

Furthermore, this study assessed the factors associated with CHE and impoverishment due to OOP medical expenditures among households of CVDs patients. The study found that the age of respondents was associated with the experience of CHE, as older patients were more likely to experience financial catastrophe. This finding is intuitive because the severity of disease conditions may increase with age in some cases which is also usually accompanied with higher OOP health expenditures. Apart from this, as individuals attain some certain ages, depending on the country, they are expected to retire from active participation in the labour force. This oftentimes mean that they are able to earn significantly lesser income compared with when they were in active employment. Usually, retired individuals receive pensions in Nigeria, but this pensions are not paid regularly. This coupled with the earlier point may have been the reason why this study showed estimates that suggests that older patients were disproportionately affected by OOP medical payments in relation to the experience of CHE. In the Barasa et al. study, results showed that households where the household head (usually the breadwinner) is unemployed and aged were associated with CHE [26]. Also, findings in Tolla et al. indicated that the age of respondents is significantly associated with the magnitude of CHE [36].

Consistent with the ideal scenario, the households of CVDs patients who had tertiary education were less likely to incur financial catastrophe due to OOP medical expenditures relative to those with no formal education. This finding is expected because it appears reasonable that there exists a strong correlation between the literacy level of household heads and the economic status of respective households. The idea is that the higher the level of education attained by the household head the more likely the economic prosperity of that household. Likewise, this study revealed that the economic status of households is significantly associated with the experience of CHE. The richest households are less likely to incur CHE relative to the poorest households. This finding has been supported by earlier studies [19, 21, 39, 43, 47]. Another variable related to the economic status of households is the occupation of the respondents. Retired and unemployed CVDs payments were more likely to experience CHE. It is however counter-intuitive that CVDs patients, who reported larger household size are less likely to incur CHE. Nonetheless, in Nigeria it is common that sometimes rich individuals maintain larger households that includes house helps and other relatives who may not necessarily be biological children of the household head.

Moreover, the pattern shown with regards to the factors associated with CHE was also observed for factors related to whether a household is poor or not. Being a female, more viable economic status and household size were significantly associated with the poverty status of the households of CHE patients. In the adjusted model, the households of patients who were females were less likely to be poor relative to those who were males. Perhaps, it can be argued that most of the households in LMICs are headed by males and are usually economically responsible for the survival of their households. In situations where the breadwinner (in this case, a male household head) becomes ill with a chronic disease and unable to work or earn lower incomes due to sick days, this may lead to unimaginable financial hardships for such households. Whereas, if the woman suffers a chronic illness while the man is able to work and support the family financially, the economic impact of chronic illness may not be as severe as what it would have been in the former scenario.

Overall, findings in this study highlights the need for a well-developed financial protection mechanism and suggests that the government needs to do more to scale-up the efforts to achieving universal healthcare coverage. Policy makers should design strategies aimed at reducing the over-reliance on OOP spending on health and increase options for prepayments to access quality healthcare services. In doing this, government through the NHIS should seek to attain full coverage of the entire population, including those in the formal and informal sectors. This can be achieved by developing a robust tax-based system as well as a social health financing system while encouraging other forms of private health insurance. Indeed, this will be pivotal to preventing a situation whereby individuals and their households are pushed into poverty as a result of large OOP payments for medical expenditures.

Study limitation

This study is not without limitations. Although, in the execution of the study, careful attention was devoted to ensuring that the information provided by the respondents were verified through the review of medical records, still it is believed that the OOP medical expenditures elicited from participants, especially in relation to inpatient care, might have been affected by recall bias. Similarly, the level of CHE and poverty headcount might be quite higher than what is reported in this study because only OOP medical expenditures incurred for the treatment of CVDs were included in the calculation of the primary outcome variables (i.e. CHE and poverty headcount) which is the focus of this study. However, when the health expenditures incurred in the treatment of other household members are considered, the financial strain and poverty rates due to OOP medical payments as a whole will be larger. Therefore, the interpretation of the findings of this study should be done with full consideration of the stated limitations.

Conclusion

This study showed that OOP medical spending for accessing healthcare services due to CVDs imposed enormous strain on household resources and increased the poverty rates among households. Given the rising level of CVDs in Nigeria, as also witnessed in many LMICs, there is a need to increase the efforts to ensure that households are not impoverished because of the need to pay OOP for healthcare services. Policies and interventions that supports universal health coverage are highly recommended.

Supporting information

S1 Data

(CSV)

Acknowledgments

The authors acknowledge the time and patience of the study participants. Also, the authors wish to thank the reviewers for their valuable comments during the review process.

Abbreviations

CVDs

Cardiovascular diseases

DALYs

Disability Adjusted Life Years

WHO

World Health Organization

LMICs

Low-and middle- income countries

OOP

Out-of-pocket

CHE

Catastrophic health expenditure

NGN

Nigerian Naira

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This research was supported by the Consortium for Advanced Research Training in Africa (CARTA). CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No—G-19-57145), Sida (Grant No:54100113), Uppsala Monitoring Centre and the DELTAS Africa Initiative (Grant No: 107768/Z/15/Z). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (UK) and the UK government. The statements made and views expressed are solely the responsibility of the Fellow.” The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017. Jul 4;70(1):1–25. doi: 10.1016/j.jacc.2017.04.052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Dalia G, Rachel K. Burden of Cardiovascular Disease (CVD) on Economic Cost. Comparison of Outcomes in US and Europe. Circ Cardiovasc Qual Outcomes. 2017;10(suppl_3):A207–A207. [Google Scholar]
  • 3.Roth GA, Huffman MD, Moran AE, Feigin V, Mensah GA, Naghavi M, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Vol. 132, Circulation. Lippincott Williams and Wilkins; 2015. p. 1667–78. doi: 10.1161/CIRCULATIONAHA.114.008720 [DOI] [PubMed] [Google Scholar]
  • 4.The World Health Organization. Cardiovascular diseases [Internet]. [cited 2020 Aug 21]. Available from: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
  • 5.Joseph P, Leong D, McKee M, Anand SS, Schwalm J-D, Teo K, et al. Reducing the Global Burden of Cardiovascular Disease, Part 1. Circ Res. 2017. Sep 1;121(6):677–94. doi: 10.1161/CIRCRESAHA.117.308903 [DOI] [PubMed] [Google Scholar]
  • 6.Yang L, Wu M, Cui B, Xu J. Economic burden of cardiovascular diseases in China. Expert Rev Pharmacoeconomics Outcomes Res. 2008. Aug;8(4):349–56. doi: 10.1586/14737167.8.4.349 [DOI] [PubMed] [Google Scholar]
  • 7.Luengo-Fernández R, Leal J, Gray A, Petersen S, Rayner M. Cost of cardiovascular diseases in the United Kingdom. Heart. 2006. Oct 1;92(10):1384–9. doi: 10.1136/hrt.2005.072173 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Gaziano TA. Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa. Vol. 94, Heart. BMJ Publishing Group Ltd; 2008. p. 140–4. doi: 10.1136/hrt.2007.128785 [DOI] [PubMed] [Google Scholar]
  • 9.Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: A systematic review. BMC Public Health BioMed Central Ltd.; Aug 6, 2018. p. 1–11. doi: 10.1186/s12889-018-5806-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.The cost of CVD | Champion Advocates Programme [Internet]. 2019. [cited 2019 Jul 3]. Available from: http://www.championadvocates.org/en/champion-advocates-programme/the-costs-of-cvd [Google Scholar]
  • 11.Leive A, Xu K. Coping with out-of-pocket health payments: empirical evidence from 15 African countries. Bull World Health Organ. 2008;86:849–856C. doi: 10.2471/blt.07.049403 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.McIntyre D, Thiede M, Dahlgren G, Whitehead M. What are the economic consequences for households of illness and of paying for health care in low-and middle-income country contexts?. Social science & medicine. 2006. Feb 1;62(4):858–65. doi: 10.1016/j.socscimed.2005.07.001 [DOI] [PubMed] [Google Scholar]
  • 13.Carapinha JL, Ross-Degnan D, Desta AT, Wagner AK. Health insurance systems in five Sub-Saharan African countries: Medicine benefits and data for decision making. Health Policy (New York). 2011. Mar 1;99(3):193–202. doi: 10.1016/j.healthpol.2010.11.009 [DOI] [PubMed] [Google Scholar]
  • 14.Okpani A, Abimbola S. Operationalizing universal health coverage in Nigeria through social health insurance. Niger Med J. 2015;56(5):305. doi: 10.4103/0300-1652.170382 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Adebiyi A. Measuring the incidence and prevalence of cardiovascular diseases in nigeria (Doctoral dissertation, Walden University).
  • 16.Ike S, Onyema C. Cardiovascular diseases in Nigeria: What has happened in the past 20 years? Niger J Cardiol. 2020;17(1):21. [Google Scholar]
  • 17.Jan S, Laba T-L, Essue BM, Gheorghe A, Muhunthan J, Engelgau M, et al. Action to address the household economic burden of non-communicable diseases. Lancet (London, England). 2018. May 19;391(10134):2047–58. doi: 10.1016/S0140-6736(18)30323-4 [DOI] [PubMed] [Google Scholar]
  • 18.Johnston KM, Lakzadeh P, Donato BMKK, Szabo SM. Methods of sample size calculation in descriptive retrospective burden of illness studies. BMC Med Res Methodol. 2019;19(1). doi: 10.1186/s12874-018-0657-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Huffman MD, Rao KD, Pichon-Riviere A, Zhao D, Harikrishnan S, Ramaiya K, et al. A Cross-Sectional Study of the Microeconomic Impact of Cardiovascular Disease Hospitalization in Four Low- and Middle-Income Countries. Malaga G , editor. PLoS One. 2011. Jun 14;6(6):e20821. doi: 10.1371/journal.pone.0020821 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Patridge EF, Bardyn TP. Research electronic data capture (REDCap). Vol. 106, Journal of the Medical Library Association. Medical Library Association; 2018. p. 142–4. [Google Scholar]
  • 21.Kwesiga B, Zikusooka CM, Ataguba JE. Assessing catastrophic and impoverishing effects of health care payments in Uganda. BMC Health Serv Res. 2015. Jan 22;15(1):30. doi: 10.1186/s12913-015-0682-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kinyanjui ND. Determinants and distribution of catastrophic health expenditures and impoverishment in Kenya (Doctoral dissertation, University Of Nairobi).
  • 23.Gotsadze G, Zoidze A, Rukhadze N. Household catastrophic health expenditure: evidence from Georgia and its policy implications. BMC health services research. 2009. Dec;9(1):1–9. …. doi: 10.1186/1472-6963-9-69 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Si Y, Zhou Z, Su M, Ma M, Xu Y, Heitner J. Catastrophic healthcare expenditure and its inequality for households with hypertension: Evidence from the rural areas of Shaanxi Province in China. Int J Equity Health. 2017;16(1). doi: 10.1186/s12939-016-0506-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Brinda EM, Kowal P, Attermann J, Enemark U. Health service use, out-of-pocket payments and catastrophic health expenditure among older people in India: The WHO study on global AGEing and adult health (SAGE). J Epidemiol Community Health. 2015;69(5). [DOI] [PubMed] [Google Scholar]
  • 26.Barasa EW, Maina T, Ravishankar N. Assessing the impoverishing effects, and factors associated with the incidence of catastrophic health care payments in Kenya. Int J Equity Health. 2017. Feb 6;16(1):1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Van Doorslaer E, O’Donnell O, Rannan-Eliya RP, Somanathan A, Adhikari SR, Akkazieva, et al. Paying out-of-pocket for health care in Asia: Catastrophic and poverty impact. Erasmus University, Rotterdam and IPS, Colombo. 2005. May. [Google Scholar]
  • 28.Xu K, Evans DB, Kadama P, Nabyonga J, Ogwal PO, Nabukhonzo P, et al. Understanding the impact of eliminating user fees: utilization and catastrophic health expenditures in Uganda. Social science & medicine. 2006. Feb 1;62(4):866–76. doi: 10.1016/j.socscimed.2005.07.004 [DOI] [PubMed] [Google Scholar]
  • 29.Ekman B. Catastrophic health payments and health insurance: Some counterintuitive evidence from one low-income country. Health Policy (New York). 2007. Oct;83(2–3):304–13. doi: 10.1016/j.healthpol.2007.02.004 [DOI] [PubMed] [Google Scholar]
  • 30.Obembe TA, Levin J, Fonn S. Prevalence and factors associated with catastrophic health expenditure among slum and non-slum dwellers undergoing emergency surgery in a metropolitan area of South Western Nigeria. PLoS One. 2021. Aug 1;16(8):e0255354. doi: 10.1371/journal.pone.0255354 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ataguba JEO. Reassessing catastrophic health-care payments with a Nigerian case study. Heal Econ Policy Law. 2012. Jul;7(3):309–26. doi: 10.1017/S1744133110000356 [DOI] [PubMed] [Google Scholar]
  • 32.Donaldson D, Weymark JA. A single-parameter generalization of the Gini indices of inequality. Journal of economic Theory. 1980. Feb 1;22(1):67–86. [Google Scholar]
  • 33.Ngcamphalala C, Ataguba JE. An assessment of financial catastrophe and impoverishment from out-of-pocket health care payments in Swaziland. Glob Health Action. 2018. Jan 31;11(1):1428473. doi: 10.1080/16549716.2018.1428473 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Xu Y, Gao J, Zhou Z, Xue Q, Yang J, Luo H, et al. Measurement and explanation of socioeconomic inequality in catastrophic health care expenditure: Evidence from the rural areas of Shaanxi Province. BMC Health Serv Res. 2015;15(1). doi: 10.1186/s12913-015-0892-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Montes J, Silwal A, Newhouse D, Chen F, Swindle R, Tian S. How much will poverty rise in Sub-Saharan Africa in 2020? [Google Scholar]
  • 36.Tolla MT, Norheim OF, Verguet S, Bekele A, Amenu K, Abdisa SG, et al. Out-of-pocket expenditures for prevention and treatment of cardiovascular disease in general and specialised cardiac hospitals in Addis Ababa, Ethiopia: a cross-sectional cohort study. BMJ Glob Heal. 2017;2:280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Jan S, Lee SW, Sawhney JP, Ong TK, Chin CT, Kim HS, et al. Catastrophic health expenditure on acute coronary events in Asia: a prospective study. Bulletin of the World Health Organization. 2016. Mar 1;94(3):193. doi: 10.2471/BLT.15.158303 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Daivadanam M, Thankappan KR, Sarma PS, Harikrishnan S. Catastrophic health expenditure & coping strategies associated with acute coronary syndrome in Kerala, India. The Indian journal of medical research. 2012. Oct;136(4):585. [PMC free article] [PubMed] [Google Scholar]
  • 39.Mutyambizi C, Pavlova M, Hongoro C, Booysen F, Groot W. Incidence, socio-economic inequalities and determinants of catastrophic health expenditure and impoverishment for diabetes care in South Africa: A study at two public hospitals in Tshwane. Int J Equity Health. 2019. May 22;18(1):1–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Njagi P, Arsenijevic J, Groot W. Understanding variations in catastrophic health expenditure, its underlying determinants and impoverishment in Sub-Saharan African countries: A scoping review. Syst Rev. 2018. Sep 11;7(1). doi: 10.1186/s13643-018-0799-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Buigut S, Ettarh R, Amendah DD. Catastrophic health expenditure and its determinants in Kenya slum communities. Int J Equity Health. 2015. May 14;14(1). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Bhojani U, Thriveni B, Devadasan R, Munegowda C, Devadasan N, Kolsteren P, et al. Out-of-pocket healthcare payments on chronic conditions impoverish urban poor in Bangalore, India. BMC Public Health. 2012;12(1). doi: 10.1186/1471-2458-12-990 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Rashad AS, Sharaf MF. Catastrophic and impoverishing effects of out-of-pocket health expenditure: new evidence from Egypt. Am J Econ. 2015. Nov;5(5):526–33. [Google Scholar]
  • 44.Rezapour A, Ghaderi H, EbadiFard Azar F, Larijani B, Reza Gohari M. Mahmood Reza Gohari. Effects of Health Out-of-Pocket Payment on HouseHolds in Iran; Catastrophic and Impoverishment: Population Based Study in Tehran (2012). Vol. 10, Life Sci J. 2013. [Google Scholar]
  • 45.McHenga M, Chirwa GC, Chiwaula LS. Impoverishing effects of catastrophic health expenditures in Malawi. Int J Equity Health. 2017. Jan 21;16(1). doi: 10.1186/s12939-017-0515-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Dorjdagva J, Batbaatar E, Svensson M, Dorjsuren B, Kauhanen J. Catastrophic health expenditure and impoverishment in Mongolia. Int J Equity Health. 2016. Jul 11;15(1). doi: 10.1186/s12939-016-0395-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Bredenkamp C, Mendola M, Gragnolati M. Catastrophic and impoverishing effects of health expenditure: new evidence from the Western Balkans. Health policy and planning. 2011. Jul 1;26(4):349–56. doi: 10.1093/heapol/czq070 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Hao Xue

10 May 2022

PONE-D-21-32628The microeconomic impact of out-of-pocket medical expenditure on the households of cardiovascular disease patients in general and specialized heart hospitals in Ibadan, NigeriaPLOS ONE

Dear Dr. Adeniji,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 24 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Hao Xue

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This research was supported by the Consortium for Advanced Research Training in Africa (CARTA). CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No--B 8606.R02), Sida (Grant No:54100113), the DELTAS Africa Initiative (Grant No: 107768/Z/15/Z) and Deutscher Akademischer Austauschdienst (DAAD). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (UK) and the UK government. The statements made and views expressed are solely the responsibility of the Fellow”

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“"This research was supported by the Consortium for Advanced Research Training in Africa (CARTA). CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No--B 8606.R02), Sida (Grant No:54100113), the DELTAS Africa Initiative (Grant No: 107768/Z/15/Z) and Deutscher Akademischer Austauschdienst (DAAD). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (UK) and the UK government. The statements made and views expressed are solely the responsibility of the Fellow".

NO - Include this sentence at the end of your statement: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ.

6. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have conducted this research in an intelligible manner and in such a way that it is also reproducible by other researchers. There are few comments highlighted and that are detailed in the attached document. Authors are recommended to engage the services of an English editor to improve the readability of the manuscript - paying close attention to the tenses used.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: tao Comments.docx

PLoS One. 2022 Jul 18;17(7):e0271568. doi: 10.1371/journal.pone.0271568.r002

Author response to Decision Letter 0


30 May 2022

May 21, 2022

Plos One

Dear Editor,

Subject: PONE-D-21-32628

The microeconomic impact of out-of-pocket medical expenditure on the households of cardiovascular disease patients in general and specialized heart hospitals in Ibadan, Nigeria

Thank you for your letter/email and the opportunity to revise our manuscript.

We have carefully considered the very valuable suggestions and comments offered by the editor and reviewers. We can say that those comments have been immensely helpful in improving the quality of our manuscript.

We hereby include the editorial comments as well as the reviewer comments below and provided a point-by-point response to all the comments. We included the section, lines and pages where the edits/revisions have been made.

The manuscript has also been scrutinized for the requirements in the author instructions, as well. All the authors contributed and agreed to the revisions.

Thank you very much

Regards,

Dr. Folashayo Adeniji

On behalf of the authors

Editor Comments:

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

Response: The authors read the Journal’s guidelines for manuscript preparation and our manuscript was formatted accordingly.

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

Response: This is noted and will be corrected when re-submitting

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This research was supported by the Consortium for Advanced Research Training in Africa (CARTA). CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No--B 8606.R02), Sida (Grant No:54100113), the DELTAS Africa Initiative (Grant No: 107768/Z/15/Z) and Deutscher Akademischer Austauschdienst (DAAD). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (UK) and the UK government. The statements made and views expressed are solely the responsibility of the Fellow”

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“"This research was supported by the Consortium for Advanced Research Training in Africa (CARTA). CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No--B 8606.R02), Sida (Grant No:54100113), the DELTAS Africa Initiative (Grant No: 107768/Z/15/Z) and Deutscher Akademischer Austauschdienst (DAAD). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (UK) and the UK government. The statements made and views expressed are solely the responsibility of the Fellow".

NO - Include this sentence at the end of your statement: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: This is noted. The funding statement has been removed from the manuscript and included in the cover letter.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

Response: The data used for this study has been uploaded.

We will update your Data Availability statement on your behalf to reflect the information you provide.

5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ.

Response: The ORCD ID of the corresponding author has been added to the Editorial Manager

6. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

Response: The ethics statement has been removed from the acknowledgement and taken to the methods section.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Response: We have looked at the references again and made necessary revisions. Kindly refer to the reference section of the manuscript.

Reviewer #1 Comments

1. Change Vancouver formatting style from (9) to [9]. [ ] is the accepted formatting style for PlosOne.

Response: Square brackets have been used in line with journal requirements.

2. On line 89. Consider changing, “This oftentimes undermine the goal….” To: “These oftentimes undermine the goal….” Or “This oftentimes undermines the goal….”

Response: This has been revised to reflect the suggestion of the reviewer. See line 90.

3. On page 499 In Authors’ contributions: Keep authors initials consistent with author names i.e Please remove FA, OL and KO and replace with KIFA. AOL and KOO.

Response: This has been revised. See line 508

4. In Acknowledgement section: It is always desirable to acknowledge the reviewers also for their roles in improving the paper

Response: The reviewer has been acknowledged in our acknowledgement section.

5. In the Tables, (clearly specify by adding “Ref” category beside all reference categories e.g <45 (Ref); Male (Ref) etc.

Response: The reference category has been identified. See Tables 5a-6b.

6. In Table 1, Under Household Positions, include what categories of people you classify as “others’ under the table as a foot note. And please change it from “Other” to “Others”.

Response: This has been included. See Table 1

7. Ensure that tense throughout the results section is reported in past tense. The tense used for reporting in the results seems to alternate between present and past tenses. For instance, on line 264…. “Relating to the occupational distribution of the respondents, 477, representing 64.11% are gainfully employed” should be rephrased as, “Relating to the occupational distribution of the respondents, 477, representing 64.11% were gainfully employed”

Response: Result section has been revised accordingly to ensure that all findings are consistently reported in past tense. See lines 265-362

8. On Line 141, the assertion that Ibadan is renowned to be the biggest city in West Africa only holds true for land mass, not for population or other parameters. Readers may be confused if this is not clearly stated. Please add, “with respect to land mass” to Line 141

Response: This statement has been revised to reflect the suggestion of the reviewer.

9. On Line 184…direct is repeated twice….” only the OOP expenditures (both direct and direct costs) pertaining” …. ought to be,” …only the OOP expenditures (both direct and indirect costs) pertaining…

Response: This has been corrected accordingly

10. On Line 110, “But, there has been no disease-specific studies examining the household-level microeconomic impact of OOP payments for the treatment of CVDs” is a pretty strong assertion to make. I believe what authors mean to say is that this kind of study has not been evaluated in detail yet in SSAs or in developing countries such as Nigeria before. I suggest revising that statement to read, “But, there has been no disease-specific studies examining the household-level microeconomic impact of OOP payments for the treatment of CVDs in Nigeria”.

Response: As suggested by the reviewer, “in Nigeria” has been included to show that the assertion relates to Nigeria.

Overall, the manuscript was read by an expert editor and corrections were made were needed.

The author wish to thank the Editor and the reviewers for their valuable comments.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Hao Xue

4 Jul 2022

The microeconomic impact of out-of-pocket medical expenditure on the households of cardiovascular disease patients in general and specialized heart hospitals in Ibadan, Nigeria

PONE-D-21-32628R1

Dear Dr. Adeniji,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Hao Xue

Academic Editor

PLOS ONE

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I do not have any other concerns about dual publication, research ethics or publication ethics. The authors have done well to address all issues raised.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Acceptance letter

Hao Xue

8 Jul 2022

PONE-D-21-32628R1

The microeconomic impact of out-of-pocket medical expenditure on the households of cardiovascular disease patients in general and specialized heart hospitals in Ibadan, Nigeria

Dear Dr. Adeniji:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Hao Xue

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Data

    (CSV)

    Attachment

    Submitted filename: tao Comments.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES